VaxInnate Corporation Receives $2.1 Million From New Jersey’s Technology Business Tax Certificate Transfer Program
1/28/2014 9:40:49 AM
CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation, a biotechnology firm pioneering a breakthrough technology platform for the development of novel vaccines, announced today that it has received $2.1 million in non-dilutive financing through New Jersey’s Technology Business Tax Certificate Transfer (NOL) Program.
Help employers find you! Check out all the jobs and post your resume.